Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Vinorelbine for HER2+ Breast Cancer Brain Metastases
NCT03933982Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive breast cancer, brain metastases, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancerbrain metastases
Beyond the preview
Go deeper on NCT03933982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03933982.